CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that it has received notice from the Nasdaq Listing Qualifications staff of the Nasdaq Stock Market that Idera is not in compliance with the minimum market value requirement for continued listing on The Nasdaq Global Market (the “MVLS requirement”) because the aggregate market value of Idera’s common stock was below $50 million for 30 consecutive business days (pursuant to Listing Rule 5450(b)(2)(A)).
